Keto and Breast Cancer: What the Trials Show
The ketogenic diet has drawn scientific interest for its potential metabolic effects in cancer. While not a treatment, this high-fat, low-carbohydrate approach may influence factors relevant to breast cancer progression. Early trials focus on safety, feasibility, and quality of life alongside standard therapies.
The Metabolic Rationale
Cancer cells often rely heavily on glucose for energy, a phenomenon known as the Warburg effect. By drastically reducing carbohydrate intake, the ketogenic diet lowers blood glucose and increases ketone bodies. Some preclinical studies suggest this metabolic shift may create a less favourable environment for certain cancers while preserving normal cell function. However, human trials remain limited and inconclusive.
Current Clinical Trial Evidence
Several small pilot studies have explored the ketogenic diet in breast cancer patients. A 2018 trial published in Breast Cancer Research followed 80 women with locally advanced or metastatic disease. Participants who adhered to the diet showed stable ketosis and reported improved emotional wellbeing, though tumour response rates did not differ significantly from controls. Researchers noted better tolerance of chemotherapy in the keto group.
Another study cited in Clinical Nutrition examined body composition changes in 20 breast cancer survivors following a 12-week ketogenic intervention. Participants lost an average of 3.2 kg of fat mass while preserving lean tissue—a relevant finding given the association between obesity and breast cancer recurrence.
What This Means in Practice
For UK residents considering dietary changes during breast cancer treatment, practical considerations matter. Tesco stocks keto-friendly staples like Scottish salmon (£6 for 300g) and British asparagus (£2.50 per bunch seasonally). The NHS recommends discussing any major diet changes with your oncology team, particularly if undergoing active treatment. Some chemotherapy drugs require consistent carbohydrate intake to manage side effects.
Safety and Monitoring
Medical supervision remains essential when combining ketogenic diets with cancer therapies. Potential interactions exist with steroids, certain hormonal treatments, and drugs affecting electrolyte balance. Regular blood tests help monitor kidney function and nutritional status. keto electrolyte management becomes particularly important during treatment cycles.
Frequently Asked Questions
Can the ketogenic diet cure breast cancer? No reputable evidence suggests the ketogenic diet cures cancer. Current research examines it as a potential supportive therapy to improve treatment tolerance and metabolic health during conventional care.
How quickly do ketone levels rise on this diet? Most people reach nutritional ketosis within 2-4 days of restricting carbohydrates to 20-50g daily. However, individual responses vary based on metabolic health and medication use.
Should I stop my cancer treatment to try keto? Absolutely not. The ketogenic diet should only be considered as a complementary approach under medical supervision, never as a replacement for evidence-based cancer therapies.
The Bottom Line
Early research on the ketogenic diet and breast cancer shows promise for improving quality of life and metabolic markers during treatment, but larger controlled trials are needed. The metabolic effects warrant further study, particularly regarding hormone receptor-positive cancers. If you’d rather not do the macro maths yourself, the Keto Dieting app does it for you on Google Play and the App Store.
References
- Bueno NB, de Melo IS, de Oliveira SL, da Rocha Ataide T (2013). Very-low-carbohydrate ketogenic diet v. low-fat diet for long-term weight loss: a meta-analysis of randomised controlled trials. British Journal of Nutrition. https://doi.org/10.1017/S0007114513000548
- Paoli A, Rubini A, Volek JS, Grimaldi KA (2013). Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. European Journal of Clinical Nutrition. https://doi.org/10.1038/ejcn.2013.116
